World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
119
Citations
73849
World Ranking
3822
National Ranking
2095

Overview

Keunchil Park is affiliated with The University of Texas MD Anderson Cancer Center in the United States. The primary focus of their research lies within the broader field of Medicine, with a significant emphasis on Oncology and Pulmonary and Respiratory Medicine. Their scholarly work spans subfields including Molecular Biology, Cancer Research, and Immunology.

The scientist's research interests cover a range of topics related to cancer, such as Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, and Lung Cancer Research Studies. Other important themes in their work include Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Gastric Cancer Management and Outcomes.

Keunchil Park has contributed to multiple research articles published in several prominent scientific journals. Frequent venues for the scientist's publications include:

  • Cancer
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Nature Communications
  • Lung Cancer

Significant recent papers from their body of work include:

  • KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors, 2020, New England Journal of Medicine
  • Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma, 2020, Nature Communications
  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020, British Journal of Cancer
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Analyses of non-coding somatic drivers in 2,658 cancer whole genomes, 2020, Nature

Collaboration is a key aspect of Keunchil Park's research activities. Frequent coauthors include:

  • Se-Hoon Lee
  • Myung-Ju Ahn
  • Jin Seok Ahn
  • Hyun Ae Jung
  • Jong-Mu Sun

Best Publications

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

    Robert Pirker;Jose R. Pereira;Aleksandra Szczesna;Joachim von Pawel

  • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

    Ji-Youn Han;Keunchil Park;Sang-We Kim;Dae Ho Lee

  • Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma.

    Nayoung Kim;Nayoung Kim;Nayoung Kim;Hong Kwan Kim;Kyungjong Lee;Yourae Hong;Yourae Hong

  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

    Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski

  • Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

    Jeeyun Lee;Cheolwon Suh;Yeon Hee Park;Young H. Ko

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

    David S. Hong;Yoon Koo Kang;Mitesh Borad;Jasgit Sachdev

  • A Transforming Growth Factor β Receptor Type II Gene Mutation Common in Colon and Gastric but Rare in Endometrial Cancers with Microsatellite Instability

    Lois L. Myeroff;Ramon Parsons;Seong Jin Kim;Lora Hedrick

  • Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta

    Keunchil Park;Seong Jin Kim;Yung Jue Bang;Jae Gahb Park

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

    Keunchil Park;Eric B Haura;Natasha B Leighl;Paul L R Mitchell

Frequent Co-Authors

Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Jin Seok Ahn
Jin Seok Ahn Sungkyunkwan University
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Jeeyun Lee
Jeeyun Lee Sungkyunkwan University
Ki-Hyun Kim
Ki-Hyun Kim Hanyang University
Won Ki Kang
Won Ki Kang Samsung Medical Center
Joon Oh Park
Joon Oh Park Samsung Medical Center
Jhingook Kim
Jhingook Kim Sungkyunkwan University
Woong-Yang Park
Woong-Yang Park Samsung Medical Center
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking alternative pathways or accelerated advancement, online healthcare degrees offer diverse options. Today’s online programs are designed for flexibility and efficiency, giving you the ability to advance your career or specialize without traditional time constraints.

For nurses ready to pursue leadership roles or higher-level clinical practice, consider enrolling in one of the short dnp programs available online, allowing you to earn a Doctor of Nursing Practice in less time. If you’re looking for a more accessible route, several easiest dnp program online options emphasize flexible coursework and supportive environments.

Those starting out in nursing might explore fast track lpn programs online, which can quickly lead to entry-level positions in healthcare. If your interest lies in mental health care, the fastest psych np program can help you become a Psychiatric Mental Health Nurse Practitioner in less time.

Whether seeking advancement or a new specialty, these online programs provide accessible and efficient pathways toward a rewarding healthcare career.

Best Scientists Citing Keunchil Park

Trending Scientists